Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 6/20 | 0.51 |
| ▸ | MAPT | P10636 | 5/20 | 0.51 |
| ▸ | NPC1 | O15118 | 5/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.51 |
| ▸ | MEN1 | O00255 | 2/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.51 |
| ▸ | GAA | P10253 | 3/20 | 0.50 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.47 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.45 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | PKM | P14618 | 1/20 | 0.44 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.44 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.44 |
| ▸ | MAOA | P21397 | 2/20 | 0.44 |
| ▸ | MAOB | P27338 | 2/20 | 0.44 |
| ▸ | OGA | O60502 | 1/20 | 0.43 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.43 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21912296 | 0.85 | ALDH1A1 (0.45) | RAB9AMAPTNPC1ALDH1A1MEN1 | |
| SCHEMBL31216581 | 0.85 | HTT (0.50) | MAPTMEN1KMT2ACYP2C19MAOA | |
| SCHEMBL5758347 | 0.83 | RAB9A (0.56) | RAB9AMAPTNPC1ALDH1A1MEN1 | |
| SCHEMBL3563236 | 0.80 | CHEK1 (0.47) | RAB9AMAPTNPC1CHEK1LMNA | |
| SCHEMBL5868882 | 0.79 | GAA (0.53) | RAB9AMAPTNPC1ALDH1A1MEN1 | |
| SCHEMBL31216537 | 0.79 | CHEK1 (0.48) | ALDH1A1GAACYP1A2CYP2C19SMN1; SMN2 | |
| SCHEMBL6560539 | 0.76 | RAB9A (0.51) | RAB9AMAPTNPC1ALDH1A1MEN1 | |
| SCHEMBL6558268 | 0.76 | RAB9A (0.51) | RAB9AMAPTNPC1ALDH1A1MEN1 | |
| SCHEMBL3561688 | 0.76 | CHEK1 (0.48) | MAPTALDH1A1CYP1A2CYP2C19POLB | |
| SCHEMBL25650489 | 0.76 | OGA (0.44) | MAPTALDH1A1MEN1KMT2ACYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7151098-B2 | Glutamate receptor antagonists | HOFFMANN-LA ROCHE INC. (US) | 2006-12-19 | — | — | US | disclosed |
| US-20060148791-A1 | Glutamate receptor antagonists | ADAM GEO | 2006-07-06 | — | — | US | disclosed |
| US-7018998-B2 | Glutamate receptor antagonists | HOFFMANN-LA ROCHE INC. (US) | 2006-03-28 | — | — | US | disclosed |
| US-6960578-B2 | Glutamate receptor antagonists | HOFFMANN-LA ROCHE INC. (US) | 2005-11-01 | — | — | US | disclosed |
| US-20050234048-A1 | Glutamate receptor antagonists | ADAM GEO | 2005-10-20 | — | — | US | disclosed |
| EP-1224175-B1 | BENZODIAZEPINE DERIVATIVES AS METABOTROPIC GLUTAMATE RECEPTOR ANTAGONISTS | HOFFMANN LA ROCHE (CH) | 2004-03-17 | — | — | EP | disclosed |
| EP-1100762-B1 | ERYTHROMYCIN DERIVATIVES WITH ANTIBIOTIC ACTIVITY | ZAMBON SPA (IT) | 2004-03-10 | — | — | EP | disclosed |
| EP-1224174-B1 | BENZODIAZEPINE DERIVATIVES AS METABOTROPIC GLUTAMATE RECEPTOR ANTAGONISTS | HOFFMANN LA ROCHE (CH) | 2003-09-17 | — | — | EP | disclosed |
| US-20030092677-A1 | Glutamate receptor antagonists | ADAM GEO (DE) | 2003-05-15 | — | — | US | disclosed |
| US-6509328-B1 | Metabotropic glutamate receptor antagonists and accordingly are useful for the treatment of a range of neurological disorders, including psychosis, schizophrenia, Alzheimer's and others | HOFFMANN-LA ROCHE INC. | 2003-01-21 | — | — | US | disclosed |
| US-6468979-B1 | ERYTHROMYCIN DERIVATIVES WITH BIHETEROCYCLIC GROUP AS SUBSTITUENT AT END OF CHAIN HAVE PARTICULARLY BROAD SPECTRUM OF ACTIVITY AND LONG DURATION OF ACTION | ZAMBON GROUP S.P.A. (IT) | 2002-10-22 | — | — | US | disclosed |
| US-6407094-B1 | 4-5-DIDEHYDRO-1,5-BENZODIAZEPIN-2-ONE DERIVATIVES; PSYCHOLOGICAL, NERVOUS SYSTEM, AND BRAIN DISORDERS; COGNITION ACTIVATORS; ALZHEIMER*S DISEASE, SCHIZOPHRENIA | HOFFMANN-LA ROCHE INC. | 2002-06-18 | — | — | US | disclosed |
| EP-1100762-A2 | ERYTHROMYCIN DERIVATIVES WITH ANTIBIOTIC ACTIVITY | ZAMBON GROUP S.p.A. (IT) | 2001-05-23 | — | — | EP | disclosed |
| WO-2000006606-A2 | ERYTHROMYCIN DERIVATIVES WITH ANTIBIOTIC ACTIVITY | ZAMBON GROUP S.P.A. (IT) | 2000-02-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030092677-A1 | Glutamate receptor antagonists | GRM1, GRM3, GRM2 | RAB9A 1527/4885MAPT 4357/4885NPC1 2855/4885 |
| US-20050234048-A1 | Glutamate receptor antagonists | GRM3, GRM1, GRM2 | RAB9A 2325/4885MAPT 4011/4885NPC1 3580/4885 |
| US-20060148791-A1 | Glutamate receptor antagonists | GRM3, GRM1, GRM2 | RAB9A 2325/4885MAPT 4011/4885NPC1 3580/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.